Ionis Pharmaceuticals (IONS), a biopharmaceutical company with a market cap of $9.15 billion, presented its outlook at the Wells Fargo Healthcare Conference on September 10, 2024, amid mixed results in its therapeutic programs and revenue challenges. The company reported a year-over-year decline in revenue to $874 million, a 7.4% drop, and a negative gross profit margin of –6.9%, reflecting ongoing financial pressures. Loss per share stood at $3.46, though analysts anticipated a 52% upside from current share prices, with a consensus range of $54 to $105 per share.
Ionis Pharmaceuticals Reports Setbacks in Key Programs Amid U.S. Healthcare Conference
Ionis Pharmaceuticals (IONS) highlighted two failed clinical trials and revenue pressures during its presentation at Wells Fargo’s 21st Annual Healthcare Conference, while emphasizing recent FDA approvals and pipeline momentum.
PA
Priya Anand · Equities & Earnings Desk · 20 Sept 2026 · 17:45 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
